Melanoma is one of the most dangerous skin malignancies due to its high metastatic tendency and high mortality. Activation of key signaling pathways enforcing melanoma progression depends on phosphorylation of tyrosine kinases, and oxidative stress. We here investigated the effect of the new bis-coumarin derivative (3,5-DCPBC) on human melanoma cell survival, growth, proliferation, migration, and intracellular redox state, and deciphered associated signal pathways. This novel derivative was found to be toxic for melanoma cells, and non-toxic for their benign counterparts, melanocytes and fibroblasts. 3,5-DCPBC inhibited cell survival, migration and proliferation of different metastatic, and non-metastatic melanoma cell lines through the profound suppression of phosphorylation of the Epidermal Growth Factor receptor, and related downstream pathways. Suppression of phosphorylation of key downstream transcription factors and different tyrosine kinases comprise JAK/STAT, SRC kinases, ERK and MAP kinases (p38alpha), all involved in melanoma progression. Simultaneous and specific targeting of multiple tyrosine kinases and corresponding key genes in melanoma cells makes 3,5-DCPBC a highly interesting anti-melanoma, and anti-metastatic drug candidate which may in the long term hold promise in the therapy of advanced melanoma.
Introduction
Malignant melanoma represents most aggressive and deadliest form of skin cancer (Stephanie et al., 2020; Liu, Das, Liu, & Huang, 2018; Prado, Svoboda, & Rigel, 2019) . Several systemic therapies (cytotoxic chemotherapy, targeted drugs, immunotherapy, hormonal therapy, radiation therapy, and biochemotherapy) have been approved by the US Food and Drug Administration (FDA) (Domingues, Lopes, Soares, & Populo, 2018; Martin & Lo, 2018) . Surgery still represents the first treatment option for primary melanoma when metastasis has not yet occurred. At later metastatic stages, systemic therapies are mandatory. The most successful treatment options against non-resettable metastatic melanoma are the in DMEM were loaded onto 8-micrometer pore Transwell inserts (upper chambers), and incubated for 2 hrs at 37 °C in 5% CO2. The lower chambers were loaded either with 600 L of 20% FBS in DMEM, chemotactic stimuli (human placental type IV collagen) at a concentration of 100 μg/µL or dissolved in 20% F B S inDMEM, and incubated for 2 hrs at 37 °C in 5% CO2. After a 4 hrs incubation period, cells were fixed, and stained using the Diff Quik® Stain kit. Non-migrated cells were removed from the upper chambers using cotton swabs. Perforated filters were removed and fixed on OT slides. An average number of migrated cells was counted in five high-power microscopic fields (HPF), randomly chosen at 20X magnification from each of the three technical and four biological replicates. Images of the cells migrated to the downside of the perforated membrane were collected using a Nikon TE300 inverted epifluorescence microscope.
Trypan blue cell viability assay
Melanoma and control cells were incubated with different concentrations of 3,5-DCPBC for 4 hrs, and viable cells were counted using Vi-CEL XR 2.03 (Beckman Coulter, USA) automated cell counter, as described earlier (Kadic, Moniz, Huo, Chi, & Kariv, 2017) .
Bromodeoxyuridine (BrdU) incorporation assay
Melanoma and control cells were seeded in 96-well plates, as described in section 2.2 followed by the treatment of 1 µM of 3,5-DCPBC/100 µL of 20% F BS in DMEM in each well for different incubation time. After incubation, 20 ul BrdU/100µL of 20% FBS DMEM was added to each well for another 2 hrs at 37 ºC, followed by fixation of cells with 1:1 acetone solution for 30 min. DNA strains were denatured with 2N HCl, and non-specific binding sites were blocked by 5% BSA dissolved in TBST. 50 µL primary anti-BrdU antibody was suspended in TBST at 1:10 dilution, and added to detect the incorporated BrdU dye. Melanoma cells and control cells in each well were then treated for 2 hrs with 50 µL Alexa Fluor conjugated 555 goat anti-mouse secondary antibody, diluted in TBST at 1:200 dilution. After washing melanoma and control cells with TBST buffer, t he fluorescence of mixture in each well was measured in 100 µL of TBST at 548 nm excitation, and 576 nm emission.
BrdU immunofluorescence staining
Cells were grown in Millicell EZ chamber slides coated with poly-l-lysine, and were further incubated with 100 µM of BrdU for 2 hrs. Melanoma cells , and contr ol cells were fixed with 1:1 acetone solution for 30 min, DNA was hydrolyzed with 2N HCl for 30 min and non-specific binding sites were blocked by 5% BSA dissolved in TBST. Melanoma, and control cells were incubated overnight with 500 µL primary anti-BrdU antibody in TBST at a 1:10 dilution, washed thrice with TBST buffer, and thereafter, treated with 500 µL Alexa Fluor conjugated 555 goat anti-mouse secondary antibody suspended in TBST at a 1:200 dilution in each well for 2 hrs at room temperature. Cell nuclei were stained with DAPI (1µL/mL of DAPI in PBS) for 10 min, cells were fixed with formaldehyde and mounted with Fluoromount (Dako). Melanoma and control cells were examined under a fluorescence microscope at 40X magnification with AxioVision A5 microscope (Zeiss Inc., Germany). BrdU positive melanoma, and control cells were counted manually from three independent images. The percentage of proliferating cells was assessed by calculating the number of BrdU-positive cells in the 3,5-DCPBC treated group, and the DMSO treated control group in 5 to 6 random fields.
The human phospho-kinase array assay, and Western blot analysis
The phosphorylation level of kinases was determined with the Proteome Profiler Array Kit (R&D Systems) following the manufacturer's instructions. Protein concentrations were determined by the Bradford protein assay. To block non-specific sites, each of the membranes was incubated in an array blocking buffer for 1 hr. 3,5-DCPBC and DMSO treated cell lysates (334 µL cell lysate/1mL of array buffer corresponding to 200 µg protein lysate) were applied on membranes, and incubated overnight. Thereafter, membranes were washed with 1X washing buffer followed by incubation with 20 mL of the detection antibody for 2 hrs on a shaker at room temperature. Membranes were thoroughly rinsed with washing buffer thrice, and further incubated with Streptavidin-HRP at room temperature for 30 min. Membranes were washed with 1X washing buffer, for 10 min, and thereafter all membranes were simultaneously exposed to SignalFire plus chemiluminescent reagents for 1 min. Phospho-kinase array data were developed on Vilber FusionFx Chemiluminescence Imager for 1to10 min with multiple exposure times.
Statistical analysis
Graph Pad Prism software 5 (GraphPad Software, Inc., SanDiego, CA) was used to analyze data. Parametric one-way analysis of variance was used with Tukey's posthoc analysis for comparison between multiple groups of 3,5-DCPBC treated, and DMSO treated groups. Student's t-test (two-tailed) was employed for comparison between the two groups of counted cells taken from representative photomicrographs. Significance was defined as P < 0.05. P values were assigned * with P < 0.01, ** with P < 0.001 and *** with P < 0.0001. R studio and Cytoscape were used for data analysis and networking analysis respectively.
Results

3,5-DCPBC induced cytotoxicity in metastatic, and non-metastatic melanoma cells
3,5-DCPBC was synthesized using 2 molecules of 4-hydroxy coumarin and 3,5-dichlorbenzaldehyde in a condensation reaction, as shown in ( Figure. 1 A). Cytotoxicity of 3,5-DCPBC was further assessed employing the MTT assay where the activity of NADPH oxidoreductase served as a measure for the extent of cellular toxicity. The results were compared with the optical density determined for non-treated control cells (20% FBS DMEM) or dimethyl sulphoxide (DMSO). We found a concentration and time-dependent increase in cytotoxicity in A375 melanoma cells upon treatment with 3,5-DCPBC ( Figure 1 B and C) . 3,5-DCPBC depicts cytotoxicity of more than 50% of melanoma cells upon incubation at concentrations of 1, 10, and 100 µM for 12 hrs (Figure 1 B) . Cytotoxicity studies of 3,5-DCPBC on WM-115, a n d m e t a s t a t i c SK-MEL-28 melanoma cells show similar results (Figure 1 D, E). To explore the specificity of 3,5-DCPBC for its cytotoxicity on melanoma cells, t he cytotoxicity of 3,5-DCPBC was further assessed on human melanocytes (NHEM), and fibroblasts (FF95). It was noted, 3,5-DCPBC did not show any cytotoxicity on human melanocytes (NHEM), and fibroblast (FF95) at both time points ( Figure 1 G and H). 
3,5 -DCPBC inhibits migration of melanoma cells
Since cell migration is a key step in tumor metastasis (Jiang et al., 2015) , inhibition of melanoma cell migration is of prime importance. Multi-chamber Transwell® migration assays were employed to assess the effect of 3,5-DCPBC on random, and directed migration of metastatic melanoma (A375, SK-MEL-28) and non-metastatic melanoma (WM-115) cells. The suppressive effect of 3,5-DCPBC was first tested at three different concentrations (0.1, 1, and 10 µM) for 4 hrs on the directed migration of A375 melanoma cells. Of note, 3,5-DCPBC effectively suppressed the directed migration of A375 melanoma cells at all concentrations in a dose-dependent manner ( Figure 2 A) . Type-IV collagen a n d 20% FBS served as a strong chemoattractant (positive controls). 3,5-DCPBC impressively inhibited 20% FBS directed A375 melanoma cell migration (Figure 2 A, B ). In fact, 3,5-DCPBC suppressed A375 melanoma cell migration by 93.1 % at a concentration of 1 µM compared to the control (Figure 2A , middle panel). Representative photomicrographs of the bottom side of the perforated membranes confirm these results (Figure 2 B) . These data imply that 3,5-DCPBC strongly suppresses A375 melanoma cell migration. In order to explore whether the migration suppressing efficacy of 3,5-DCPBC is a more general property, other metastatic and non-metastatic melanoma cells were assessed. Of note, both the directed migration of the metastatic SK-MEL-28 melanoma cells, and the non-metastatic WM-115 melanoma cells were similarly suppressed by 3,5-DCPBC ( Figure 2C ). Figure 2D depicts the percentage of 3,5-DCPBC suppression of directed melanoma cell migration. This strong inhibitory effect of 3,5-DCPBC on directed melanoma cell migration is a true anti-migratory effect, and not due to a 3,5-DCPBC induced cytotoxicity ( Figure 2E ). A375 melanoma cells were found to be viable in the range of 90.9 to 93.3% in 3,5-DCPBC treated group as compared to DMSO control groups (97.3%, and 95.03%, respectively) during the studied migration period of 4 hrs.
3,5 -DCPBC diminishes metastatic melanoma cell proliferation
The effect of 3,5-DCPBC was further explored on the proliferation of metastatic A375 melanoma cells as a prime event in melanoma progression. For this purpose, BrdU incorporation was studied as previously described (Bundscherer et al., 2008) . The DNA thymidine analog 5-bromo-2'-deoxyuridine (BrdU) was allowed to incorporate into rapidly growing metastatic melanoma cells during t he S phase of the cell cycle in the presence, and absence of 3,5-DCPBC and thereafter was detected by an antibody directed against BrdU, employing a fluorometer at 548 and 576 nm excitation and emission, respectively. 3,5-DCPBC efficiently suppressed melanoma cell proliferation at 48 hrs of treatment ( Figure 3A) . This anti-proliferative 3,5-DCPBC effect corresponds to an average of the relative fluorescence of 1, compared to 4.9 of the DMSO control at the same time point ( Figure 3A) . In a complementary approach, BrdU positive cells from immunofluorescence photomicrographs were quantitated, and the percentage of BrdU positive cells were significantly reduced ( Figure 3B ). These data indicate the anti-proliferative effect of compound 3,5-DCPBC on A375 metastatic melanoma cells.
3,5 -DCPBC does not alter the intracellular redox state
Metastatic melanoma progression is known to driven by reactive oxygen species (ROS) be in part, and in particular, the migration and proliferation of metastatic melanoma cells are enhanced by an intracellular increase in superoxide (O 2 .-) and hydrogen peroxide (H2O2) levels (Bisevac et al., 2018; Dan Dunn, Alvarez, Zhang, & Soldati, 2015; Denat, Kadekaro, Marrot, Leachman, & Abdel-Malek, 2014) . (F) Differential phospho-regulation is plotted using MA plot. X-axis represent the mean expression and y-axis represents log2 fold change, the genes that are more than two-fold differentially regulated are shown in blue whereas the non-significant one is shown in grey. (G) Phosphorylation motifs were analyzed from the 16 differentially downregulated phosphokinase motifs from (F). (H) represents the pathway analysis carried out depicting those genes from the 16 regulated phosphosites. X-axis represents the gene ratio, whereas the associated pathways are represented in y-axis. The color of the circles represents the level of significance as p values adjusted.
observed suppression of proliferation, and migration on melanoma cells is not due to antioxidant properties of 3,5-DCPBC. 
Molecular mechanism of action of 3,5-DCPBC
To gain insight into the mechanism of how 3,5-DCPBC inhibits melanoma cell survival, growth, proliferation, and migration, a phospho-proteome profiling array was employed. A375 melanoma cells were treated with 3,5-DCPBC at a concentration of 1 µM for 4, and 18 hrs. For each time point, a total of 43 kinase phosphorylation sites and 2 related proteins (HSP, and tumor suppressor proteins) were analyzed. A significant effect of compound 3,5-DCPBC was observed on 31 phosphorylation sites of 25 different kinases at 4 hrs, and 11 phosphorylation sites of 6 different kinases at 18 hrs. Altogether, 36 phosphorylation sites of 27 different kinases were found to be potential targets of 3,5-DCPBC as opposed to the DMSO control, (Figure 4 A, C, and B, D) . A list of non-affected kinases is attached as ( Supplementary Tables 1 and 2 ). Densitometric analysis of significant phosphorylation sites of the 25 kinases along with their associated P values is shown in Figure 4 E. Sixteen different kinases were more than 2-fold down-regulated upon treatment with 3,5-DCPBC as compared to DMSO (Figure 4 F) . The MA plot depicts Log2 fold changes on y-axis, and Log2 mean expression on x-axis (Figure 4 F) . Eleven kinases did not show any significant changes. Among the 16 differentially down-regulated phosphokinases, predominantly members of the family of the tyrosine kinase family were suppressed, A, B, C, D) A375 metastatic melanoma cells were treated with 1 µM 3,5-DCPBC for 18 hrs. Cell lysates from the DMSO treated (control) (A), and 3,5-DCPBC treated (B) A375 melanoma cells were incubated with PVDF-membranes with anchored antibodies for phosphor-T183,221/Y185,223-JUNK1/2/3 (spot 1), phosphor-T183-AMPKα1(spot 2), phosphor-S376/S360-MSK1/2 (spot 3), phosphor-S133-CREB (spot 4), phosphor-S21/S9-GSK-3αβ/ (spot 5), and phosphor-Y420-Yes (spot 6). Membranes were developed with appropriate secondary antibodies, and spots were detected using a chemiluminescence based assay, as described in Material and Methods. (E) The phosphorylation (activation) state of kinases was determined by densitometry analysis from data of Fig.  5 (A, B, The tyrosine kinase phospho-motif (blue filled circles) is the most affected phospho-motif in A375 melanoma cells treated with 3,5-DCPBC as compared to threonine (green filled circles) or serine (pink filled circles). Phospho-motif mapping thus allowed us to uncover major kinases and signaling pathways targeting key genes for melanoma progression. Pathway analysis was further employed for the most suppressed kinases with downregulation of phospho-motifs to explore which signaling pathways are most prominently affected (Figure 4 H) . The x-axis represents the gene ratio which is presented as % of total differential gene expression (DGE) in all GO clusters, and the y-axis represents the associated pathway. The color refers to the P-value, and the count as the number of occurrences of this gene per GO cluster. Pathway analysis with the differentially down-regulated phosphor-motifs depict receptor tyrosine kinases, inflammatory interleukins and ERK1/2, AKT, and mTOR as the major signaling cascades that are affected after treatment of melanoma cells with 3,5-DCPBC. Briefly, phosphor tyrosine modulation at a specific residue of Epidermal Most excitingly, it is endowed with the potential to target multiple kinases to prevent cellular migration (via SRC), ER stress survival (via p38α), proliferation and protein synthesis (via AKT/mTOR). Red circles with p indicate the genes in the signaling cascade, which could be post translationally regulated with phosphorylation at kinase sites as well as which were found to be significantly downregulated in melanoma cell after 3,5-DCPBC treatment in comparison with the controls phosphorylation of serine or threonine kinases was less frequently affected (Figure 4 G) . The y-axis represents the fold change, and the x-axis represents the position of the phospho-sites in the gene amino acid sequence (Figure 4 G) .
Catenin Y654 . In order to understand whether inhibition of phosphosites following treatment of 375 melanoma cells with 3,5-DCPBC will persist for 18 hrs, phosphokinase array analysis was performed ( Figure 5A , B, C, D): Densitometric analysis from A-D depicts the downregulation of phosphor-sites is not maintained in all identified phosphokinases ( Figure 5 E) . Of note, as shown in the blue box of the correlation plot (Fig.  5F) , EFGFR, AKT1, 2, and 3 and STAT3 at 18 hrs of 3,5 DCPBC are still profoundly suppressed. These phosposites are mainly from tyrosine kinases ( Figure 5G ), and they impact on the genes involved in tyrosine kinase signaling ( Figure 5H ).
Discussion
The major unprecedented finding of this study is that the newly synthesized bis-coumarin derivative referred to as 3,5-DCPBC has profound inhibitory properties on key steps of malignant melanoma progression (Wirbel, Cutillas, & Saez-Rodriguez, 2018) . Accordingly, proliferation, migration, and survival of melanoma cells -by contrast to melanocytes, their benign counterpart, or fibroblasts -are impressively downregulated in vitro in the presence of moderate concentrations of 3,5-DCPBC. The strong effect on key features of melanoma progression is not due to any antioxidant property of 3,5-DCPBC, though ROS have been reported to be associated with melanoma pathophysiology, but rather a consequence of its outstanding suppressive potential of the major different tyrosine phosphokinases involved in melanoma progression (see summary graph Figure. 6 ). In fact, phosphokinases modulate several cellular functions (Nishi, Shaytan, & Panchenko, 2014) , and activation of multiple phosphokinases has been implicated in melanoma, and many cancers including autophosphorylation of Epidermal Growth Factor Receptor (EGFR) (Boone et al., 2011; Davies, 2012) Of note, compound 3,5-DCPBC significantly diminished the phosphorylation of the Y 1086 of EGFR and Y 751 of PDGFR at 4 hrs (Figure 4 E, F, Figure 5E and Supplementary Table-1). As phosphorylation of these residues of EGFR and PDGFR regulates various signal transduction pathways (mTOR, SFK, JAK-STAT, and MAPK) involved in cell proliferation, cell migration as well as cell survival, are found to be hyperphosphorylated in various cancers including melanomas (Dratkiewicz, Simiczyjew, Pietraszek-Gremplewicz, Mazurkiewicz, & Nowak, 2019; Girotti et al., 2013; Nazarian et al., 2010; Welsh, Rizos, Scolyer, & Long, 2016) , we further studied the downstream pathways, and their associated genes that are regulated through EGFR Y1086 phosphorylation ( Figure 4 H) . Hyperphosphorylation of mTOR at its threonine Thr 2446 , serine residues (Ser 2448, and Ser 2481 ) via EGFR-ERK-S6K1 and PI3K/AKT axis (Copp, Manning, & Hunter, 2009 ), linked to growth in various types of cancers and melanoma (Holroyd & Michie, 2018) , was markedly downregulated upon 3,5-DCPBC treatment, as confirmed by downregulation of 16 genes within the mTOR pathway (Figure 4 F) . Suppression of phosphorylation (activation) of the mTOR pathway (mTOR, PRAS40, and ERK1/2/3) was observed only at 4 hrs after 3,5-DCPBC treatment. EGFR phosphorylation can activate the Src family of kinases (SFKs) (Halaban et al., 2019) , they consequently play key roles in cell differentiation, motility, proliferation, and survival (Irwin, Bohin, & Boerner, 2011) , Tyrosine phosphorylation of members of SFKs including SRC Y419 , LYN Y397 , LCK Y394 , FYNY 420 , Yes Y426 , FGR Y 412 , HCK Y41, and FAK Y319 were all profoundly down-regulated in A375 malignant melanoma cells treated with 3,5-DCPBC. The finding that the newly synthesized compound 3,5-DCPBC has the potential to simultaneously suppress many phospho-tyrosine kinases, among them EGFR and SRC, is of major clinical relevance. In fact, the simultaneous inhibition of tyrosine phosphorylation of EGFR and SRC kinases has recently been reported to overcome the frequently developing BRAF resistance in melanoma (Girotti et al., 2013) . Of major importance among other contributing downstream signaling
